Co-Authors
This is a "connection" page, showing publications co-authored by SARINA ANNE PIHA-PAUL and GOLDY C GEORGE.
Connection Strength
0.923
-
Factors affecting symptom presentation in an early-phase clinical trials clinic patient population. Invest New Drugs. 2020 08; 38(4):1166-1174.
Score: 0.177
-
Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. J Med Internet Res. 2019 03 14; 21(3):e10348.
Score: 0.169
-
Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center. JCO Clin Cancer Inform. 2018 12; 2:1-14.
Score: 0.165
-
Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. Cancer. 2016 Nov 15; 122(21):3401-3409.
Score: 0.140
-
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Sci Rep. 2022 08 23; 12(1):14367.
Score: 0.054
-
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Oncologist. 2021 07; 26(7):588-596.
Score: 0.049
-
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. J Immunother Cancer. 2020 10; 8(2).
Score: 0.047
-
Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clin Cancer Res. 2017 Aug 01; 23(15):4155-4162.
Score: 0.038
-
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer. 2014 Jul 15; 120(14):2164-73.
Score: 0.030
-
Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy. J Cancer Res Clin Oncol. 2013 Jun; 139(6):963-70.
Score: 0.028
-
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Invest New Drugs. 2013 Aug; 31(4):918-26.
Score: 0.027